Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Current Deferred Revenue for 3 consecutive years, with $23684.0 as the latest value for Q2 2022.

  • On a quarterly basis, Current Deferred Revenue fell 83.39% to $23684.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $23684.0, a 83.39% decrease, with the full-year FY2020 number at $2.3 million, changed N/A from a year prior.
  • Current Deferred Revenue was $23684.0 for Q2 2022 at Inhibikase Therapeutics, down from $142619.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.3 million in Q4 2020 to a low of $23684.0 in Q2 2022.
  • A 3-year average of $935848.2 and a median of $696984.0 in 2021 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 83.39% in 2022; the steepest drop was 83.39% in 2022.
  • Inhibikase Therapeutics' Current Deferred Revenue stood at $2.3 million in 2020, then tumbled by 93.87% to $142619.0 in 2021, then crashed by 83.39% to $23684.0 in 2022.
  • Per Business Quant, the three most recent readings for IKT's Current Deferred Revenue are $23684.0 (Q2 2022), $142619.0 (Q2 2021), and $1.3 million (Q1 2021).